Research Xchange Forum hosted by the international pharma and laboratory supplier Sartorius will take place on February 22 and 23, 2017, in Goettingen, Germany. This industry platform that addresses scientists and staff from academic research institutes and industry will be dedicated entirely to oncology.
Keynote presentations given by internationally recognised scientists and representatives from research and development will provide insights into the latest developments of their specific cancer research and therapy approaches.
In addition to providing information on gene therapies and cancer immunotherapy using monoclonal antibodies, the conference will additionally focus on DNA repair mechanisms, drug delivery and cancer stem cell research.
In her keynote address, Professor Maja Banks-Köhn, PhD, of the European Molecular Biology Laboratory (EMBL) will report on new interdisciplinary approaches in the inhibition of cancer-promoting phosphatases.
“As a leading pharmaceutical and laboratory equipment supplier, we are well aware of the challenges of translating research findings into clinical practice,” stated Michael Melingo, member of the Group Executive Committee and President of the Lab Products & Services Division at Sartorius. “With this Forum, we aim to offer our customers and all those engaged in this field a platform for entering into a dialog and to accelerate this translation process.”
According to current market figures, cancer therapy drugs account for nearly 90 percent of late phase clinical trials in the drug discovery industry. Nearly 600 cancer drug candidates are currently in the advanced clinical trial phases. Around half of these active pharmaceutical ingredients are recombinant drugs, including 16 gene therapeutics, more than 80 monoclonal antibodies and 15 biosimilars.
Progress in oncology is particularly based on excellent collaboration between drug discovery and applied research. “We are consistently implementing a number of measures to enable researchers to reach these goals faster by breakthrough innovations, such as the new cell analysis platform for immuno-oncology, which has been integrated into the Sartorius portfolio following the acquisition of IntelliCyt,” stated Terry Dunlay, who heads the Bioanalytics unit. This is also reflected in the subjects that will be covered by the scientific forum.
“Cancer challenges us from both a social and a business perspective. In sharing information with our customers, we experience on a daily basis how important it is to transfer knowledge from drug discovery into effective treatment. With our Xchange Forum, we would primarily like to offer new ideas and inspiration to participants for their work,” said Karen Storm, Vice President of Marketing of the Lab Products & Services Division.
Source of Market Figures: IMS Health Study: “Global Market for Cancer Treatments Grows to $107 Billion in 2015, Fueled by Record Level of Innovation,” June 2016
Click here to find out more
16th Annual Laboratory Management and Medicine (MEDLAB) Congress – a key laboratory show worldwide - is now a stand-alone event, following 14 years of success alongside the flagship healthcare show, Arab Health.
Welcoming over 35,000 laboratory professionals to do business with 700 international companies, the event will showcase the latest laboratory management and diagnostics technologies available to the market worldwide, as well as feature 11 CME-accredited conference tracks discussing up-to-the-minute discoveries by over 80 local and international leading speakers.
MEDLAB will take place from 6-9 February 2017 at the Dubai International Convention & Exhibition Centre, Dubai, UAE.
Occupying six exhibition halls, the show will uncover over 400 cutting-edge medical laboratory products and services from 700 participating exhibitors representing 38 countries.
Additionally, the MEDLAB exhibition reinforces its position as an international hub showcasing a truly international base of suppliers with 15 dedicated country pavilions.
The congress features 11 CME-accredited conference tracks focusing on bridging the gap between test utilisation and test interpretation, concentrating on the correlation of roles between laboratory professionals and clinicians. Attended by more than 10,000 delegates from around the globe, the programme brings a global appeal with over 80 local and international speakers.Click here to find out more
On April 4, 2017 the first international Stem Cell Community Day will take place in Hamburg, Germany.
Experts from academia and industry will discuss the status quo, perspectives, and challenges in stem cell cultivation for research and therapy, according to the event’s motto: “Bioprocessing Technologies in Stem Cell Research – Challenges and Chances for Commercialization”.
Key note speakers are Steve Oh, PhD, from the Bioprocessing Technology Institute in Singapore, Dr Stefan Braam, CEO of Pluriomics (Netherlands), and Todd McDevitt, PhD, principal investigator at the Gladstone Institutes (USA).
Attendees can expect a comprehensive programme including talks, a poster exhibition with final awarding, as well as hands on demonstrations of instruments and consumables for stem cell cultivation. Dr. Robert Zweigerdt from the Hannover Medical School (Germany) will be the scientific chairman.
The Stem Cell Community Day is organised by the leading life science company Eppendorf AG. “The commercial use of stem cell-based technologies requires reliable methods for the large-scale production of stem cells in consistent quality. We are very excited to bring together international experts and learn about the latest findings and trends in this exciting new field,” comments Dr. Karl Rix, Vice President Marketing, Portfolio & Support Bioprocess, Eppendorf.
The event will take place at the Hotel Crowne Plaza Hamburg – City Alster. The conference language is English. Registration is open until March 29, 2017. Poster abstracts can be submitted until March 10, 2017.
For registration, the full programme, and further information, click HERE.Click here to find out more